<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851734</url>
  </required_header>
  <id_info>
    <org_study_id>LX214-01</org_study_id>
    <nct_id>NCT00851734</nct_id>
  </id_info>
  <brief_title>A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lux Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lux Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-man study for the purpose of determining the safety and tolerability of
      LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ocular irritation</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>LX214 0.02%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LX214 ophthalmic solution 0.02%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LX214 0.2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voclosporin ophthalmic solution</intervention_name>
    <description>0.02%, 0.2% t.i.d. or b.i.d.</description>
    <arm_group_label>LX214 0.02%</arm_group_label>
    <arm_group_label>LX214 0.2%</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No systemic disease as determined by a physical examination, clinical laboratory
             evaluation, and an ECG

          -  Schirmer's I Test â‰¥ 10mm/5 minutes with anesthesia

          -  Corrected Snellen acuity of 20/40 or better in both eyes

        Exclusion Criteria:

          -  Subjects diagnosed with any ocular disease other than refraction error

          -  Subjects with intraocular pressure &gt;21 mmHg

          -  Use of a contact lens within 7 days prior to administration of the first dose

          -  Subjects with history of ocular surgery

          -  Subjects with a history of laser refractive surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Product Investigations</name>
      <address>
        <city>Conshohocken</city>
        <state>Pennsylvania</state>
        <zip>19428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

